PBL Assay Science offers two lines of Human IFN-Alpha ELISA kits; VeriKine-HS, a high-sensitivity, all-subtype assay (LLOQ 1.95 pg/ml, detects all 12 IFN-Alpha subtypes) for low-abundance samples such as healthy donor serum; and VeriKine, a standard-sensitivity, multi-subtype assay (11 of 12 subtypes, broad pg/ml range) suited to tissue culture media and stimulated samples where IFN-Alpha is more abundant.
VeriKine-HS Human IFN-Alpha ELISA Kits (High Sensitivity, All-Subtype)
VeriKine-HS kits are designed for low pg/ml quantification of total IFN-Alpha across all 12 known subtypes, in healthy and disease serum, plasma, and tissue culture media (TCM). Because multiple IFN-Alpha subtypes are typically present simultaneously in a biological sample, all-subtype (pan-subtype) reactivity is essential for determining the true total IFN-Alpha level when a single-subtype or partial-subtype assay will systematically undercount.
Best for: healthy donor cohorts, early/low-titer disease timepoints, autoimmune serum studies (e.g., lupus, SLE), and any application where total IFN-Alpha burden, not one subtype, is the readout of interest.
VeriKine Human IFN-Alpha ELISA Kits (Standard Sensitivity, Multi-Subtype)
VeriKine kits are built for situations where IFN-Alpha is expected to be readily present and its detection matters more than resolving every last subtype at the lowest possible concentration, such as tissue culture supernatants following viral infection or TLR-agonist stimulation, where robust induction typically pushes IFN-Alpha well above baseline.
Best for: applications where IFN-Alpha is expected to be relatively abundant and the priority is confirming and quantifying a strong response rather than detecting trace, low-abundance levels